Methods and compositions for the inhibition of transplant rejection
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/16
C07K-014/705
C07K-016/46
G01N-033/68
A61K-038/17
C07K-016/28
출원번호
US-0392399
(2010-08-31)
등록번호
US-9005616
(2015-04-14)
국제출원번호
PCT/US2010/047384
(2010-08-31)
§371/§102 date
20120224
(20120224)
국제공개번호
WO2011/026132
(2011-03-03)
발명자
/ 주소
Langermann, Solomon
Liu, Linda
출원인 / 주소
Amplimmune, Inc.
대리인 / 주소
Pabst Patent Group LLP
인용정보
피인용 횟수 :
2인용 특허 :
82
초록▼
Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effe
Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.
대표청구항▼
1. A method for inhibiting or reducing rejection of a tissue or organ transplant in a human subject, comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprisinga dose of 3 mg/kg to 25 mg/kg of a fusion protein comprising a B7-H4 polypeptide comprising
1. A method for inhibiting or reducing rejection of a tissue or organ transplant in a human subject, comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprisinga dose of 3 mg/kg to 25 mg/kg of a fusion protein comprising a B7-H4 polypeptide comprising the IgV domain of SEQ ID NO:63 or SEQ ID NO:64 fused to a second polypeptide or fused to a linker peptide fused to a second polypeptide,wherein at least two of the dosage units are administered at least two days apart and within two weeks,to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce rejection of the tissue or organ transplant in the subject for at least a week post administration. 2. A method for inhibiting or reducing rejection of a tissue or organ transplant in a human subject, comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprisinga dose of 3 mg/kg to 25 mg/kg of a fusion protein comprising a B7-H4 polypeptide comprising the IgV domain of SEQ ID NO:63 or SEQ ID NO:64 fused to a second polypeptide or fused to a linker peptide fused to a second polypeptide comprisingthe hinge, CH2 and CH3 regions of an immunoglobulin,wherein at least two of the dosage units are administered at least two days apart and within two weeks,to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce rejection of the tissue or organ transplant in the subject for at least a week post administration. 3. The method of claim 1, wherein the pharmaceutical dosage unit further comprises a second therapeutic agent. 4. The method of claim 3 wherein the second therapeutic agent is selected from the group consisting of glucocorticoid fluticasone, salmeterol; antibodies to IL-12, IL-6, IFN-γ, IL-23, IL-22, IL-21 and IL-4; vitamin D3, CTLA-4-Ig, belatacept, dexamethasone, and combinations thereof. 5. The method of claim 1 wherein the transplant is an allogeneic transplant. 6. The method of claim 1, wherein the transplant is a skin graft, a tissue transplant, an organ transplant, or a bone marrow transplant. 7. A method for treating one or more symptoms of graft versus host disease (GVHD) in a human subject, comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprisinga dose of 3 mg/kg to 25 mg/kg of a fusion protein comprising a B7-H4 polypeptide comprising the IgV domain of SEQ ID NO:63 or SEQ ID NO:64 fused to a second polypeptide or fused to a linker peptide fused to a second polypeptide,wherein at least two of the dosage units are administered at least two days apart and within two weeks,to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce one or more symptoms of GVHD in the subject for at least a week post administration. 8. A method for treating one or more symptoms of graft versus host disease (GVHD) in a human subject, comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprisinga dose of 3 mg/kg to 25 mg/kg of a fusion protein comprising a B7-H4 polypeptide comprising the IgV domain of SEQ ID NO:63 or SEQ ID NO:64 fused to a second polypeptide or fused to a linker peptide fused to a second polypeptide,wherein the second polypeptide comprises the hinge, CH2 and CH3 regions of an immunoglobulin,wherein at least two of the dosage units are administered at least two days apart and within two weeks,to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce one or more symptoms of GVHD in the subject for at least a week post administration. 9. A method for inhibiting or reducing rejection of a tissue or organ transplant in a human subject comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprising a dose of 3 mg/kg to 25 mg/kg of a fusion protein comprising a B7-H4 polypeptide comprising the IgV domain of B7-H4 fused to a second polypeptide or fused to a linker peptide fused to a second polypeptide, wherein at least two of the dosage units are administered at least two days apart and within two weeks,to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce rejection of tissue or organ transplant in the subject for at least a week post administration. 10. The method of claim 2, wherein the immunoglobulin is a human IgG1. 11. A method for inhibiting or reducing rejection of a tissue or organ transplant in a human subject, comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprisinga dose of 3 mg/kg to 25 mg/kg of a fusion protein comprising the amino acid sequence of SEQ ID NO:130wherein at least two of the dosage units are administered at least two days apart and within two weeks,to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce rejection of tissue or organ transplant in the subject for at least a week post administration. 12. The method of claim 8, wherein the immunoglobulin is a human IgG1. 13. The method of claim 8, wherein the second polypeptide comprises the hinge, CH2 and CH3 regions of an immunoglobulin. 14. The method of claim 13, wherein the immunoglobulin is a human IgG1. 15. A method for treating one or more symptoms of graft versus host disease (GVHD) in a human subject, comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprising 3 mg/kg to 25 mg/kg of a fusion protein comprising the amino acid sequence of SEQ ID NO:130wherein at least two of the dosage units are administered at least two days apart and within two weeks,to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce one or more symptoms of GVHD in the subject for at least a week post administration. 16. A method for treating one or more symptoms of graft versus host disease (GVHD) in a human subject comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprising a dose of 3 mg/kg to 25 mg/kg of a fusion protein comprising a B7-H4 polypeptide comprising the IgV domain of B7-H4 fused to a second polypeptide or fused to a linker peptide fused to a second polypeptide, wherein at least two of the dosage units are administered at least two days apart and within two weeks,to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce one or more symptoms of graft versus host disease (GVHD) in the subject for at least a week post administration. 17. The method of claim 1, wherein at least three of the dosage units are administered at least two days apart and within two weeks. 18. The method of claim 1, wherein at least two of the dosage units are administered at least two days apart and within one week. 19. The method of claim 1, wherein at least three of the dosage units are administered at least two days apart and within one week. 20. The method of claim 9, wherein at least three of the dosage units are administered at least two days apart and within two weeks. 21. The method of claim 9, wherein at least two of the dosage units are administered at least two days apart and within one week. 22. The method of claim 9, wherein at least three of the dosage units are administered at least two days apart and within one week. 23. The method of claim 11, wherein at least three of the dosage units are administered at least two days apart and within two weeks. 24. The method of claim 11, wherein at least two of the dosage units are administered at least two days apart and within one week. 25. The method of claim 11, wherein at least three of the dosage units are administered at least two days apart and within one week. 26. The method of claim 15, wherein at least three of the dosage units are administered at least two days apart and within two weeks. 27. The method of claim 15, wherein at least two of the dosage units are administered at least two days apart and within one week. 28. The method of claim 15, wherein at least three of the dosage units are administered at least two days apart and within one week. 29. The method of claim 1, wherein the administration is effective to reduce rejection of the tissue or organ transplant in the subject for at least 10 days post administration. 30. The method of claim 1, wherein the administration is effective to reduce rejection of the tissue or organ transplant in the subject for at least two weeks post administration. 31. The method of claim 1, wherein the administration is effective to reduce rejection of the tissue or organ transplant in the subject for at least three weeks post administration. 32. The method of claim 7, wherein the administration is effective to reduce one or more symptoms of GVHD in the subject for at least 10 days post administration. 33. The method of claim 7, wherein the administration is effective to reduce one or more symptoms of GVHD in the subject for at least two weeks post administration. 34. The method of claim 7, wherein the administration is effective to reduce one or more symptoms of GVHD in the subject for at least three weeks post administration. 35. The method of claim 11, wherein the administration is effective to reduce rejection of the tissue or organ transplant in the subject for at least 10 days post administration. 36. The method of claim 11, wherein the administration is effective to reduce rejection of the tissue or organ transplant in the subject for at least two weeks post administration. 37. The method of claim 11, wherein the administration is effective to reduce rejection of the tissue or organ transplant in the subject for at least three weeks post administration. 38. The method of claim 15, wherein the administration is effective to reduce one or more symptoms of GVHD in the subject for at least 10 days post administration. 39. The method of claim 15, wherein the administration is effective to reduce one or more symptoms of GVHD in the subject for at least two weeks post administration. 40. The method of claim 15, wherein the administration is effective to reduce one or more symptoms of GVHD in the subject for at least three weeks post administration.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (82)
Sette Alessandro ; Gaeta Federico ; Grey Howard M. ; Sidney John ; Alexander Jeffrey L., Alteration of immune response using pan DR-binding peptides.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Skotnicki Jerauld S. (Allentown NJ) Palmer Yvette L. (Newtown PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Skotnicki Jerauld S. (Allentown NJ) Palmer Yvette L. (Newtown PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Mitcham,Jennifer L.; King,Gordon E.; Algate,Paul A.; Fling,Steven P.; Retter,Marc W.; Fanger,Gary R.; Reed,Steven G., Compositions and methods for the therapy and diagnosis of ovarian cancer.
Herzig Yaacov,ILX ; Sterling Jeff,ILX ; Veinberg Alex,ILX ; Sklarz Benjamin,ILX ; Lidor Ramy,ILX ; Bahar Eliezer,ILX, Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically a.
Ladner Robert C. (3827 Green Valley Iamsville MD 21754), Computer based system and method for determining and displaying possible chemical structures for converting double- or m.
Chen,Lieping; Strome,Scott E., Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Johnson Kevin Stuart,GBX ; Winter Gregory Paul,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX ; Waterhouse Peter Michael,AUX, Methods for producing members of specific binding pairs.
Winter Gregory Paul,GBX ; Johnson Kevin Stuart,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX, Methods for producing members of specific binding pairs.
Winter Gregory Paul,GBX ; Johnson Kevin Stuart,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX, Methods for producing members of specific binding pairs.
Holliger Kaspar-Philipp,GBX ; Griffiths Andrew David,GBX ; Hoogenboom Hendricus Renerus Jacobus Matheus,BEX ; Malmqvist Magnus,SEX ; Marks James David ; McGuinness Brian Timothy,GBX ; Pope Anthony Ri, Multivalent and multispecific binding proteins, their manufacture and use.
Queen Cary L. (Los Altos CA) Schneider William P. (Mountain View CA) Selick Harold E. (Belmont CA), Polynucleotides encoding improved humanized immunoglobulins.
Hoogenboom Hendricus R. J. M. (Cambridge GBX) Baier Michael (Frankfurt DEX) Jespers Laurent S. A. T. (Tervuren BEX) Winter Gregory P. (Cambridge GBX), Production of chimeric antibodies - a combinatorial approach.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Waranis Robert P. (Chazy NY) Harrison Maureen M. (St. Albans VT) Leonard Thomas W. (Plattsburgh NY) Enever Robin P. (Rouses Point NY), Rapamycin formulation for IV injection.
Deboer Herman A.,NLX ; Strijker Rein,NLX ; Heyneker Herbert L. ; Platenburg Gerard,NLX ; Lee Sang He,NLX ; Pieper Frank,NLX ; Krimpenfort Paul J. A.,NLX, Transgenic bovine.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.